25LBA Impact of baseline genetic heterogeneities on progression-free survival (PFS) in patients (pts) with advanced BRAFV600-mutated melanoma treated with cobimetinib (COBI) + vemurafenib (VEM) in the phase 3 coBRIM study

Grant A. McArthur, A. Ribas, Claus Garbe et al.|European Journal of Cancer|2015

Cited by 10